$9.46
-2.2%eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
No Revenue Data
EXOZ has not reported any revenue values in the available annual periods.
EXOZ • NASDAQ
| eXoZymes, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
REVENUE | |||||
GROSS PROFIT | |||||
(0.0) | (267.4K) | (0.0) | (147.8K) | (59.4K) | |
0.0 | -267.4K | 0.0 | -147.8K | -59.4K | |
OPERATING INCOME | |||||
(9.7M) | (5.7M) | (1.8M) | (1.2M) | (1.2M) | |
(5.9M) | (3.8M) | (1.3M) | (836.8K) | (779K) | |
(3.7M) | (1.9M) | (527.5K) | (348.1K) | (454.5K) | |
-9.7M | -5.9M | -1.8M | -1.3M | -1.3M | |
PRE-TAX INCOME | |||||
0.0 | 77.6K | 100.0 | 98.0 | 0.0 | |
(96K) | (0.0) | -70.1K | (0.0) | (0.0) | |
452.5K | 70.8K | -199.9K | 98.0 | 83.7K | |
-9.3M | -5.9M | -2M | -1.3M | -1.2M | |
NET INCOME | |||||
-105.2K | (0.0) | (42.3K) | (63.6K) | (0.0) | |
-9.2M | -5.9M | -2M | -1.4M | -1.2M |
EXOZ - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 10, 2026 | April 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 05, 2026 | January 29, 2026 | 2026 | |
S-3 S-3 N/A | January 16, 2026 | January 16, 2026 | ||
8-K 8-K 2025 N/A | December 12, 2025 | December 11, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 |
Continue your EXOZ research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.